Dermatology · Fairfax, VA
NPI
1811973951
Since 2005
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
3700 Joseph Siewick Dr, 404
Fairfax, VA, 22033
Phone (703) 620-8900
Groups this clinician bills Medicare through
Medicare paid, 2024
$250K
4,624 services
Medicare patients, 2024
947
Average age 75
Drug cost, 2024
$286K
839 prescriptions
Company payments, 2025
$230
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kathy D Tieu was code 17003 (destruction skin lesion), 1,736 times for 330 patients. In total Kathy D Tieu billed 4,624 services in 40 codes, and Medicare paid $250K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-02-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 1,736 | 330 | $6.06 | $11K |
| 99214 Office E&M - Established | Office | 831 | 703 | $99.83 | $83K |
| 17000 Destruction Skin Lesion | Office | 483 | 409 | $41.12 | $20K |
| 17110 Destruction Skin Lesion | Office | 328 | 303 | $94.06 | $31K |
| 99213 Office E&M - Established | Office | 239 | 225 | $66.25 | $16K |
| 11102 Skin Biopsy | Office | 201 | 190 | $75.57 | $15K |
| 11301 Removal or Shaving of Skin Growth | Office | 123 | 96 | $93.17 | $11K |
| 11103 Skin Biopsy | Office | 98 | 68 | $48.76 | $4,778 |
| 17004 Destruction Skin Lesion | Office | 95 | 82 | $152.46 | $14K |
| 11300 Removal or Shaving of Skin Growth | Office | 92 | 68 | $60.29 | $5,546 |
| 99204 Office E&M - New | Office | 44 | 44 | $108.27 | $4,764 |
| 11305 Removal or Shaving of Skin Growth | Office | 41 | 31 | $65.53 | $2,687 |
| 17111 Destruction Skin Lesion | Office | 40 | 37 | $112.61 | $4,504 |
| 11306 Removal or Shaving of Skin Growth | Office | 38 | 35 | $104.32 | $3,964 |
| 11311 Removal or Shaving of Skin Growth | Office | 37 | 31 | $117.70 | $4,355 |
By year: 2022 $367K for 6,403 services; 2023 $385K for 6,861 services; 2024 $250K for 4,624 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 87205 General Laboratory | 13 | 13 | $4.18 | $54.34 |
Medicare prescription drug claims, 2024
In 2024, the drug Kathy D Tieu prescribed most often to Medicare patients was Clobetasol Propionate, with 140 prescriptions and refills. In total Kathy D Tieu wrote 839 Medicare prescriptions that cost $286K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Clobetasol Propionate Generic | 140 | 151 | 76 | $6,991 |
| Ketoconazole Generic | 106 | 114 | 53 | $1,863 |
| Doxycycline Hyclate Generic | 97 | 149 | 24 | $2,576 |
| Doxycycline Ir-Dr Doxycycline Monohydrate | 51 | 59 | Under 11 | $26K |
| Triamcinolone Acetonide Generic | 48 | 56 | 30 | $391 |
| Minoxidil Generic | 45 | 128 | 18 | $314 |
| Gabapentin Generic | 37 | 45 | Under 11 | $373 |
| Metronidazole Generic | 30 | 33 | 20 | $2,412 |
| Finasteride Generic | 24 | 52 | Under 11 | $195 |
| Terbinafine Hcl Generic | 22 | 51 | Under 11 | $86.16 |
| Pimecrolimus Generic | 19 | 29 | Under 11 | $6,627 |
| Fluorouracil Generic | 17 | 19 | 16 | $1,189 |
| Desonide Generic | 16 | 18 | 13 | $709 |
| Cosentyx Sensoready (2 Pens) Secukinumab | 14 | 14 | Under 11 | $120K |
| Dupixent Syringe Dupilumab | 14 | 14 | Under 11 | $61K |
Brand drugs: 90 claims; generic drugs: 749 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kathy D Tieu $230 ($230 in general payments such as food, travel and fees) from 5 companies. The largest payer was Pfizer Inc. with $125.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.